PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals' stock has been impacted by financial results, clinical trial updates for rezatapopt, and analyst ratings. The company reported its Third Quarter 2025 and Full Year 2025 financial results, including its cash position of $112.9 million as of December 31, 2025. Updated rezatapopt monotherapy interim data from the PYNNACLE Phase 2 trial showed a 34% overall response rate, with a 46% ORR in the ovarian cancer cohort. The publication of rezatapopt data in the New England Journal of Medicine and the FDA granting Orphan Drug Designation for rezatapopt were also significant events. The stock has experienced fluctuations, with analysts providing a consensus "buy" rating and a median target price of $5.20, while bearish views cite concerns about rezatapopt's toxicity profile.

As a clinical-stage company, PMV Pharmaceuticals, Inc. does not have commercially available products that exhibit demand seasonality. Demand for future products will likely be driven by medical need and clinical efficacy rather than seasonal patterns.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations. Their lead product candidate, rezatapopt, is being evaluated in a Phase 2 clinical trial for tumor-agnostic diseases and the company plans to submit an NDA for platinum-resistant/refractory ovarian cancer in Q1 2027.

PMV Pharmaceuticals, Inc. is headquartered in Princeton, New Jersey, United States. Clinical trials for rezatapopt are multicenter and conducted across global regions.

PMV Pharmaceuticals' brand reputation has been positively influenced by scientific advancements and clinical trial progress, including the publication of rezatapopt data in the New England Journal of Medicine and presentations at major oncology conferences. The granting of Orphan Drug Designation for rezatapopt also contributes positively to its reputation. However, concerns about rezatapopt's toxicity profile could pose a reputational risk.

PMV Pharmaceuticals, Inc. has a significant institutional ownership base, with 67 institutional owners and shareholders holding a total of 37,466,628 shares as of April 8, 2026. Institutions hold approximately 52% of the company's shares, the general public holds about 34.7%, individual insiders own around 3.37%, and hedge funds hold approximately 9.92%. There has been insider selling activity by OrbiMed Advisors LLC.